Aurora Cannabis (ACB) Earnings Date & Reports

Aurora Cannabis delivered total net revenue of CAD $94.2 million, surpassing consensus estimates around CAD $92 million and up 7% YoY from CAD $88.2 million. Global medical cannabis net revenue hit a record CAD $76.2 million, exceeding expectations with 12% YoY growth, fueled by 17% international increases. Consumer cannabis net revenue fell 48% YoY to CAD $5.2 million, reflecting strategic de-emphasis on lower-margin recreational sales.

Adjusted gross margin before fair value adjustments rose to 62% overall and 69% on medical cannabis sales, in line with or slightly above expectations. Adjusted EBITDA of CAD $18.5 million fell slightly short of the prior year's CAD $19.4 million but demonstrated operational efficiency. The company posted a net loss from continuing operations of CAD $1.7 million, improved from prior periods but versus a CAD $28.1 million gain YoY due to one-time factors. Reported adjusted EPS was approximately $0.09 USD, narrowly missing consensus of $0.10 USD, though revenue beat bolstered positives. Free cash flow remained robust at CAD $15.5 million, supporting a strong cash position of CAD $154.4 million with no recourse debt in the core cannabis business.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your investment strategy.

Market Reaction and Investor Sentiment

Following the February 4, 2026 release, ACB shares declined about 5% to close at $3.75 USD on elevated volume of over 3 million shares, reflecting disappointment over the EPS miss and YoY EBITDA dip despite the revenue beat. Investor sentiment was mixed: positives included record medical revenue and reaffirmed guidance, but concerns lingered around consumer segment weakness and GAAP losses. Analysts noted the medical focus as a long-term strength amid industry consolidation.

Forward Outlook and Key Factors to Monitor

Aurora reaffirmed its Fiscal 2026 guidance, projecting global medical cannabis net revenue of CAD $269 million to CAD $281 million, implying 10% to 15% full-year growth. Consolidated adjusted EBITDA is expected at CAD $52 million to $57 million, supported by favorable sales mix and efficiencies.

Investors should watch Q4 results, due in June 2026, for sustained medical momentum, particularly in Europe where regulatory changes could boost demand. Plant propagation revenue, seasonal at 65-75% in the first half of the calendar year, remains a diversifier.

Key factors include international expansion, gross margin trends (targeting strength via medical emphasis), and cash flow generation to fund potential M&A (mergers and acquisitions). Broader industry dynamics, such as U.S. rescheduling progress and Canadian regulatory updates, could influence demand. Cost controls and inventory management (currently CAD $191.1 million) are vital amid economic pressures.

Overall, Aurora's debt-free core business and CAD $299.9 million working capital position it well, but execution on guidance will be crucial heading into FY2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations